Essex Bio-Technology Limited disclosed that on 26 June 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange at HKD 2.70 per share, for a total consideration of HKD 0.14 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell to 566.28 million shares from 566.33 million, representing a marginal reduction of 0.0088%. Treasury shares increased to 723,000, lifting treasury holdings to approximately 0.13% of the total issued shares of 567.01 million.

The buyback was executed under the general mandate granted on 26 May 2026, which authorises Essex Bio-Technology to repurchase up to 56.70 million shares. Cumulative repurchases under this mandate now stand at 723,000 shares—about 1.28% of the authorised limit—leaving roughly 55.98 million shares available for future buybacks.

All shares acquired on 26 June 2026 were retained as treasury shares; none have been cancelled. In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 26 July 2026.